Literature DB >> 7023529

Regular versus symptomatic aerosol bronchodilator treatment of asthma.

G L Shepherd, M R Hetzel, T J Clark.   

Abstract

Regular treatment with salbutamol or placebo aerosols was compared in a double-blind study in 18 asthma patients. Although symptom scores and respiratory function tests were not significantly different, wheezing attacks requiring additional puffs of a standard salbutamol aerosol were significantly more frequent during the period on placebo when patients were receiving symptomatic treatment only. Thus regular treatment with bronchodilator aerosols provides better control of asthma than symptomatic use alone.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7023529     DOI: 10.1016/0007-0971(81)90057-7

Source DB:  PubMed          Journal:  Br J Dis Chest        ISSN: 0007-0971


  8 in total

Review 1.  The safety of beta agonists in asthma.

Authors:  A H Morice
Journal:  Clin Investig       Date:  1992-10

Review 2.  Long- versus short-acting beta 2-agonists. Implications for drug therapy.

Authors:  L P Boulet
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

Review 3.  Is current treatment increasing asthma mortality and morbidity?

Authors:  E A Mitchell
Journal:  Thorax       Date:  1989-02       Impact factor: 9.139

4.  Exercise-induced asthma in athletes.

Authors:  J A Roberts
Journal:  Sports Med       Date:  1988-10       Impact factor: 11.136

Review 5.  The current debate concerning beta-agonists in asthma: a review.

Authors:  K F Chung
Journal:  J R Soc Med       Date:  1993-02       Impact factor: 5.344

Review 6.  A more logical approach to asthma.

Authors:  M R Hetzel
Journal:  Postgrad Med J       Date:  1984-03       Impact factor: 2.401

Review 7.  The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology.

Authors:  M R Sears; D R Taylor
Journal:  Drug Saf       Date:  1994-10       Impact factor: 5.606

Review 8.  Major reduction in asthma morbidity and continued reduction in asthma mortality in New Zealand: what lessons have been learned?

Authors:  J Garrett; J Kolbe; G Richards; T Whitlock; H Rea
Journal:  Thorax       Date:  1995-03       Impact factor: 9.139

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.